What is Leerink Partnrs’ Estimate for GPCR Q1 Earnings?

Structure Therapeutics Inc. (NASDAQ:GPCR) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Structure Therapeutics in a research report issued to clients and investors on Monday, March 3rd. Leerink Partnrs analyst D. Risinger forecasts that the company will earn ($0.24) per share for the quarter. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Structure Therapeutics’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.29) EPS, FY2025 earnings at $1.80 EPS and FY2029 earnings at $1.03 EPS.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01.

Several other research firms also recently weighed in on GPCR. HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. JMP Securities restated a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Stifel Nicolaus started coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, William Blair started coverage on shares of Structure Therapeutics in a report on Friday. They issued an “outperform” rating for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Trading Down 5.9 %

GPCR opened at $22.34 on Tuesday. The company’s fifty day moving average price is $26.45 and its two-hundred day moving average price is $33.47. Structure Therapeutics has a 1-year low of $19.61 and a 1-year high of $62.74. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -30.19 and a beta of -2.75.

Institutional Trading of Structure Therapeutics

A number of large investors have recently added to or reduced their stakes in GPCR. Deep Track Capital LP increased its holdings in Structure Therapeutics by 129.4% during the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock worth $75,936,000 after buying an additional 1,579,492 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in Structure Therapeutics by 196.5% during the third quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock worth $54,348,000 after buying an additional 820,589 shares during the last quarter. Janus Henderson Group PLC boosted its position in Structure Therapeutics by 18.0% during the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after purchasing an additional 602,609 shares during the period. Vestal Point Capital LP boosted its position in Structure Therapeutics by 105.4% during the third quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after purchasing an additional 590,000 shares during the period. Finally, Boxer Capital Management LLC bought a new position in Structure Therapeutics during the fourth quarter worth about $13,560,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.